A First Look at Phase 2 ArMaDa Data - Takeaways - MDSpire

A First Look at Phase 2 ArMaDa Data

Arshad M. Khanani, MD, FASRS, discusses phase 2 findings for OCU410, an investigational gene therapy for geographic atrophy. A phase 3 program is expected to begin later this year.

  • By

  • Arshad M. Khanani, MD, MA, FASRS

  • July 15, 2026

  • 2 min

Share

  • 1

    OCU410 is an investigational gene therapy for geographic atrophy, presented by Dr. Arshad M. Khanani at the 2026 ASRS meeting.

  • 2

    The phase 2 ArMaDa study involved two dose cohorts of OCU410 and a control arm, each with 17 patients.

  • 3

    A 34% reduction in geographic atrophy growth was observed in the medium-dose cohort compared to the control.

  • 4

    OCU410 was well tolerated, with no reported cases of retinal vasculitis, occlusive retinal vasculitis, or endophthalmitis.

  • 5

    A phase 3 program for OCU410 is expected to begin later this year.

Original Source(s)

A First Look at Phase 2 ArMaDa Data

  • by Arshad M. Khanani, MD, MA, FASRS

  • July 15, 2026

Related Content

OTX-TKI: Inside the SOL-1 Data

At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

CMS Proposal Would Cut Payment for Same-Day Injection Visits

The proposed Physician Fee Schedule for 2027 includes changes affecting intravitreal injections, E/M services, and physician payment.

OLN324: Why Size May Matter

David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.